ASCO 2019 | DIRVA: intratumorally injected durvalumab for cervical cancer

Gemma Kenter

Gemma Kenter, MD, PhD, of the Amsterdam Centre for Oncological Gynaecology, Amsterdam, The Netherlands, tells about the DIRVA trial which investigated intratumorally injected durvalumab for the treatment of cervical cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video